BAM-15
Mitochondrial protonophore uncoupler
- Class
- Mitochondrial uncoupler
- Half-life
- Not characterized
- Route
- Oral
- Cadence
- Daily
- Evidence
- Animal data primarily
Overview
BAM-15 is a synthetic mitochondrial uncoupler — a molecule that makes your cells burn fuel faster by short-circuiting the mitochondrial energy factory. It dissipates the proton gradient that normally drives ATP synthesis, forcing mitochondria to keep burning fat and glucose just to maintain function. The result in mice: fat loss without eating less, improved insulin sensitivity, and no change in lean mass or body temperature. It's the kind of molecule people hope will be DNP without the lethal side effects.
The catch: there are zero published human studies. All the fat-loss, metabolic, and anti-inflammatory data come from cell cultures and rodent models. It was originally identified by Merck in 2006, but never advanced to clinical trials. The compound on the research-chemical market is unregulated — no quality control, no verification that what's in the vial is actually BAM-15 or dosed correctly.
Unlike older uncouplers like DNP, BAM-15 doesn't depolarize the plasma membrane and appears to have a wider safety margin in animal studies — no runaway hyperthermia, no overt toxicity at effective doses. But that safety story is built entirely on preclinical data, and mitochondrial uncouplers have a narrow therapeutic window even in the best case.
A 2026 study confirmed BAM15 has high targeting ability to the liver and effectively improves hepatic lipid metabolism disorders in high-fat diet mice, with superior proton uncoupling activity compared to DNP and FCCP in this tissue.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use by any regulatory authority. The compound on the research market is unregulated — purity, identity, and dose accuracy vary wildly between suppliers.
- All safety data are from animal and cell studies. There are no published human trials. The therapeutic window (effective dose vs toxic dose) for mitochondrial uncouplers is historically narrow.
- Mitochondrial uncouplers as a class can cause hyperthermia, tachycardia, and metabolic acidosis if overdosed. BAM-15 appears safer than DNP in rodents, but the human dose-response curve is completely unknown.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching BAM-15.
- Body composition (fat mass vs lean mass — scale weight alone misses the point)
- Core body temperature (uncouplers can push this up if overdosed)
- Resting heart rate and blood pressure
- Fasting glucose and HbA1c
- Liver enzymes (ALT, AST) — some animal data show hepatic lipid changes
- Subjective: energy level, heat intolerance, sweating
Frequently asked questions
What is BAM-15?
Mitochondrial protonophore uncoupler. BAM-15 is a synthetic mitochondrial uncoupler — a molecule that makes your cells burn fuel faster by short-circuiting the mitochondrial energy factory. It dissipates the proton gradient that normally drives ATP synthesis, forcing mitochondria to keep burning fat and glucose just to maintain function. The result in mice: fat loss without eating less, improved insulin sensitivity, and no change in lean mass or body temperature. It's the kind of molecule people hope will be DNP without the lethal side effects.
How is BAM-15 administered?
Oral, typically daily.
What is the half-life of BAM-15?
Not characterized — Pharmacokinetics studied only in rodents; human half-life unknown.
Is BAM-15 approved for human use?
BAM-15 is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for BAM-15?
Evidence tier: Animal data primarily. Kenwood et al. 2014 (Mol Metab) first characterized BAM15 in vitro: EC50 of 270 nM for uncoupling in L6 myoblast mitochondria (with reported averages around 1.4 μM across different cell types), with no plasma-membrane depolarization up to 100 μM in C2C12 myotubes.
What is commonly monitored when researching BAM-15?
Commonly tracked markers + signals: Body composition (fat mass vs lean mass — scale weight alone misses the point), Core body temperature (uncouplers can push this up if overdosed), Resting heart rate and blood pressure, Fasting glucose and HbA1c, Liver enzymes (ALT, AST) — some animal data show hepatic lipid changes, Subjective: energy level, heat intolerance, sweating.
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.